Date: Mar 25, 2013 Source: Business Wire (
click here to go to the source)
ALBUQUERQUE, N.M.--(BUSINESS WIRE)--Azano Pharmaceuticals Inc. has announced the commercial availability of the high affinity and selective G-protein coupled estrogen receptor, (GPER or GPR30) agonist G-1 and antagonists G-15 and G-36. Azano will be actively fulfilling domestic and international orders through its website, www.azanopharma.com, to research professionals beginning March 22, 2013.
The discovery of GPER, the newest member of the estrogen receptor family, represents a potential novel therapeutic target. GPER has been reported to play a role in multiple diseases, such as breast and ovarian cancer, diabetes, and multiple sclerosis. However, further characterization of the physiological and pathological properties of GPER is required to determine the receptor's contribution to human disease development. Azano's high-affinity and selective, research use only, pharmacological ligands, G-1, G-15, and G-36, will allow research professionals to decipher the biological function and clinical relevance of the novel receptor.
G-1, G-15, and G-36 exhibit no or minimal cross reactivity with the classic estrogen receptors, ERα and ERβ. Recent publications have reported that G-1, a potent agonist, does not bind to either ERα or ERβ in competitive binding bindings. G-15 and G-36 are also potent antagonists. The small molecules inhibit both estrogen (17β-estradial) and G-1 mediated cell signaling in vivo. G-15 is reported to induce low levels of gene transcription via ERα in vivo, which led to the creation of G-36. G-36 was found to diminish the genomic cross-reactivity without compromising antagonist efficacy. Thus, G-1, G-15, and G-36 represent valuable tools to resolve the functions of GPER in multiple assays and model systems that simultaneously express the classical estrogen receptors.
The use of Azano's ligands, combined with tools such as siRNA and knockout animal models, will lead to an enhanced understanding of GPER and the potential development of novel therapeutics to a multitude of human diseases. For further information visit www.azanopharma.com or call 505-200-9540.
About Azano Pharmaceuticals: Azano is a privately funded company in Albuquerque, NM that is committed to harnessing the power of small molecules and proteins to develop innovative therapies. In addition to the commercialization of the GPER ligands, Azano is actively pursuing the development of a C-reactive protein (CRP) derivative to treat Systemic Lupus Erythematosus (SLE) and other autoimmune diseases.
Contacts
Azano Pharmaceuticals Inc.
Michael Perrine, 505-200-9540
Business Development Executive
mperrine@azanopharma.com
5901 Indian School Rd
Albuquerque, NM 87110
